NICE medicines evaluation director Helen Knight said: “We know how important it is for people with these types of cancer to have more treatment options that enable them to maintain or improve their quality of life.
“For adults with this type of early breast cancer, being able to have a targeted treatment after surgery and chemotherapy will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease.
“Olaparib represents an important development in the treatment of early breast and advanced prostate cancer and today’s announcement addresses a significant need by giving people with these types of cancer access to an effective, targeted treatment.”
The latest decision by NICE reverses its earlier draft decision not to recommend the medicine for adults who already received chemotherapy before or after surgery.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.